Synlogic Inc (SYBX) - Total Assets
Based on the latest financial reports, Synlogic Inc (SYBX) holds total assets worth $16.55 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Synlogic Inc (SYBX) shareholders funds for net asset value and shareholders' equity analysis.
Synlogic Inc - Total Assets Trend (2013–2024)
This chart illustrates how Synlogic Inc's total assets have evolved over time, based on quarterly financial data.
Synlogic Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Synlogic Inc's total assets of $16.55 Million consist of 99.8% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Synlogic Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SYBX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Synlogic Inc's current assets represent 99.8% of total assets in 2024, an increase from 98.9% in 2013.
- Cash Position: Cash and equivalents constituted 95.1% of total assets in 2024, down from 97.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Synlogic Inc Competitors by Total Assets
Key competitors of Synlogic Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Synlogic Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.65 | 2.71 | 12.87 |
| Quick Ratio | 2.65 | 2.71 | 12.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.27 Million | $13.06 Million | $98.55 Million |
Synlogic Inc - Advanced Valuation Insights
This section examines the relationship between Synlogic Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.70 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -73.8% |
| Total Assets | $19.83 Million |
| Market Capitalization | $7.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Synlogic Inc's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Synlogic Inc's assets decreased by 73.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Synlogic Inc (2013–2024)
The table below shows the annual total assets of Synlogic Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $19.83 Million | -73.76% |
| 2023-12-31 | $75.55 Million | -31.85% |
| 2022-12-31 | $110.86 Million | -36.55% |
| 2021-12-31 | $174.74 Million | +21.48% |
| 2020-12-31 | $143.84 Million | -23.72% |
| 2019-12-31 | $188.57 Million | +34.37% |
| 2018-12-31 | $140.34 Million | +40.76% |
| 2017-12-31 | $99.70 Million | +55.38% |
| 2016-12-31 | $64.17 Million | -29.42% |
| 2015-12-31 | $90.92 Million | +825.36% |
| 2014-12-31 | $9.82 Million | -58.52% |
| 2013-12-31 | $23.68 Million | -- |
About Synlogic Inc
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-system… Read more